Bioxcel Therapeutics (BTAI) Stock Statistics & Valuation Metrics

Bioxcel Therapeutics has a market cap or net worth of $51.97M. The enterprise value is $104.56M.

Bioxcel Therapeutics has 14,556,743 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bioxcel Therapeutics’s return on equity (ROE) is 0.64 and return on invested capital (ROIC) is -399.01%.

The current PE Ratio of Bioxcel Therapeutics is ―. Bioxcel Therapeutics’s PEG ratio is ―.

In the last 12 months, Bioxcel Therapeutics had revenue of 2.27M and earned -59.60M in profits. Earnings per share was -23.51.

In the last 12 months, operating cash flow was -55.77M and capital expenditures 0.00, giving a free cash flow of -55.77M billion.

Bioxcel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Bioxcel Therapeutics upcoming earnings date is Nov 13, 2025, TBA (Confirmed).

Bioxcel Therapeutics as a current ratio of 1.68, with Debt / Equity ratio of -100.95%

In the past 12 months, Bioxcel Therapeutics has paid 0.00 in taxes.

Bioxcel Therapeutics EV to EBITDA ratio is -2.00, with an EV/FCF ratio of -1.23.

Bioxcel Therapeutics has $17.43M in cash and marketable securities with $108.69M in debt, giving a net cash position of $91.25M billion.

Gross margin is -151.61%, with operating margin of -2967.56%, and net profit margin of -2630.14%.

The average price target for Bioxcel Therapeutics is $7.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy